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1. Introduction
The classic case of aortic stenosis is a healthy middle-aged patient with/without symptoms,
but in practical life, patients with severe calcific aortic valve come with several and severe
comorbidities such as advanced age, coronary artery disease, atherosclerotic aorta, significant
left ventricular dysfunction. Aortic valve replacement (AVR) is the only options in these
patients, and it requires patient-by-patient analysis of clinical, echocardiograhic, and hemo‐
dynamic data with associated pathologies. The curative treatment of calcific aortic valve
stenosis is the replacement of the aortic valve with a prosthetic valve, and selection of a perfect
prosthetic valve is the main goal to get a successful treatment. But, there is no any perfect heart
valve prosthesis which may mimic the characteristics of the normal native aortic valve:
excellent hemodynamics, life-long durability, thromboresistance, and excellent implantability.
That means that native valve disease will be traded for prosthetic valve disease and the
outcome of AVR is affected by the type of prosthetic valve. Mechanical valves are non-limited
durable, but have a substantial risk of hematologic complications (thromboemboli, thrombotic
obstruction, hemorrhage related life-long anticoagulation therapy) with/without hemolysis
potential. In contract, bioprosthetic valves have a low risk of thromboembolism without
anticoagulation, but their durability is limited by calcific or noncalcific tissue deterioration.
Biological prostheses, especially homografts, are often believed to be the substitute of choice
in AVR, but the limited availability of homografts prevents their more broadly usage. To
overcome this problem and all possible complications of mechanical valves, xenogenic
biological prostheses have been developed. The design of bioprosthetic valves purports to
mimic the anatomy of the native aortic valve and their flow characteristics are better than
mechanical valves, whereas stentless bioprostheses have hemodynamic performance similar
to the healthy native aortic valve. Although stented bioprostheses can be implanted easier,
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they decrease the effective orifice area due to the rigid stent and result turbulent flow through
the valve. Stented valves also increase stress at the attachment of the stent which cause earlier
primary tissue failure. Stentless biologic valves have been introduced into clinical practice to
solve all these problems and to reproduce the anatomy and function of the native aortic valve,
but their clinical use has still not exceeded the number of stented aortic bioprostheses because
of more demanding technique of implantation. To gain more widespread clinical use and
general recommendation of stentless bioprostheses, their advantages and simple implantation
techniques must be popularized.
It is believed that the aortic root is probably the best stent for the native or prosthetic aortic
valve. The anatomy and function of the aortic root may dampen the mechanical stress to which
the leaflets are subjected during diastole. The ideal stentless prosthesis should have no
synthetic materials, preserve the aortic root dynamics, restore flexibility and distensibility of
the native valve annulus after decalcification, and have minimal xenograft aortic wall, short
implantation time, and excellent hemodynamic performance to facilitate the recovery of left
ventricular function.
1.1. Historical background
Homografts were the first biological prostheses used in clinical practice to treat aortic valve
stenosis in early 1960s, and they were the first stentless valves, too [1,2]. The authors used the
aortic root of the patient to secure the homograft aortic valve in the subcoronary position. The
most complicated implantation technique and the restricted availability of homografts
prevented their widespread usage. First stentless pig and calf xenografts were used in limited
patients, but the valves were abandoned because of poor tissue fixation [3]. Stented biopros‐
theses were considered as the gold standard for several years, but abnormal stress on the
leaflets was believed to decrease durability. To overcome this problem with a rigid stent on
the aortic position, stentless bioprostheses were re-introduced in the middle of 80's [4], whereas
new designed stentless xenografts were proposed and popularized in daily use at the begin‐
ning of 1990s [5]. The main problem (early failure of bioprostheses) was solved with new
bioengineering improvement (antimineralization, zero-pressure fixation) [6]. The other
problem was partial dehiscence when the heterograft contained muscular bar resulting
paravalvular leakage in the area corresponding to the muscular bar, and this problem was
abolished with a fine Dacron cloth covered the outside wall of the stentless porcine aortic valve
along its inflow [7]. Recognizing the range of aortic root variability and disease of the root
itself, the concept of stentless valve replacement was expanded to replacement of the entire
aortic root. Full root replacement with a bioprosthesis brought the challenges of homeostasis
and coronary reimplantation. In spite of hemodynamic advantages proven for the root
replacement technique, acceptance was slowed by risk/benefit ratio concerns. The whole aortic
root could be prepared and implanted with modified root inclusion or subcoronary implant
techniques.
Biological stentless valve can be prepared by pulmonary autograft, homograft, xenograft,
autologous or xenogenic pericardium. Pulmonary autograft has limited durability beyond the
first decade [8]. The same problem has been observed with homografts in the aortic position,
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especially in younger patients, which are less durable than commercially available stentless
bioprostheses and cannot be recommended as the ideal device [9]. The use of the patients own
pericardium for constructing a heart valve prosthesis is biologically more appealing than the
use of animal tissue or heterologous material. The feasibility of autologous pericardial stentless
aortic valve was shown in an animal study [10]. The feasibility and durability of truly stentless
autologous pericardial AVR sutured directly onto the aortic wall has been also performed in
human recently [11]. Stentless porcine or pericardial xenogenic bioprostheses have been
introduced to get better long-term durability and become a routine device when a stentless
biologic valve is implanted.
There are a lot of stentless bioprostheses with/without the aortic root in the market, but some
of them are not used widespread and implantation of a few xenografts is stopped (Table 1).
The first modern (first generation) stentless valves were glutaraldehyde-fixed porcine
prostheses with a fully scalloped shape or a complete aortic root (Figure 1). The most preferred
approach was root replacement technique because subcoronary approach needed more suture
line. The second generation of stentless valves improved the technical difficulties related to
free-hand implantation with two rows of sutures for subcoronary implantation of porcine
bioprostheses (Figure 2). The third generation of stentless prostheses are made by xenogenic
pericardium, because the pericardial valve is free from the compromises of the porcine aortic
root, it is flexible, and easy to implant either with an interrupted or running suture technique
(Figure 3). There are different xenogenic pericardial valves (bovine or equine), and horse
pericardium is thinner, however, stronger than the bovine pericardium and also much more
pliable. The fourth generation of stentless valves are produced by a proprietary process and
the unique conditioning technology paves the way for autologous repopularization of the
valve in patients. The durability of current bioprosthetic heart valves is diminished by
glutaraldehyde-associated leaflet calcification or by the host immune reaction. As a novel
tissue engineering approach to improving replacement heart valve durability, a new acellular
(nonglutaraldehyde-fixed) tissue heart valve for autologous recellularization is developed to
limit xenograft antigenicity. As no glutaraldehyde is used in the whole process lack of
calcification and also lack of toxicity, and the method delivers a very pliable valve with very
low gradients. To use of autologous pericardium fixed with glutaraldehyde avoids any
immune reaction between the host and the implanted heart valve and so minimizes tissue
calcification and pannus formation. The last generation of stentless valves provides avoidance
of suture lines during AVR: closed [transcatheter (transfemoral or transapical)] or open
(transaortic = sutureless) techniques (Figure 4).
2. Hemodynamic recovery
Every effort should be made to avoid moderate prosthesis-patient mismatch during AVR.
Stentless valves enable to select the largest bioprosthesis to the patient's annulus and provide
better aortic root and valve behavior, larger effective orifice area (EOA), reduced transpros‐
thetic gradient and greater left ventricular mass regression.
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To prevent early or late prosthetic failure, maintenance of the aortic root with physiological
anatomy must be the primary goal during AVR with a stentless prosthesis. Any kind of
bioprosthetic valve will deviate from native aortic valve in terms of leaflet dynamics. Stiffening
of the aortic root either by glutaraldehyde or by stent degenerates the opening (wrinkles and
blurry edges of leaflets) and closing (asynchronism) behavior of native aortic valve leaflets.
 (A) 
(B) 
St Jude Toronto SPV St Jude Medical-Biocor 
Koehler Elan Labcor CryoLife-O'Brien 
St Jude SVP Root Edwards Prima Plus 
Medtronic Freestyle Koehler Elan Root 
Figure 1. First generation bioprostheses (Porcine Stentless Xenografts) A) Scalloped stentless porcine bioprostheses B)
Root stentless porcine bioprostheses.
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Stented valves fixe the native commissures and do not allow cyclic change of the commissural
dimension as it normally occurs. This cyclic expansion of the commissural area serves
reduction of stress on the leaflets, which is preserved by stentless bioprostheses. Second, the
intrinsically obstructive nature of the stented bioprostheses increases pressure gradient and
creates turbulent flow patterns, however, normal laminar flow patterns can be restored after
AVR with stentless tissue valves. The opening and closing of the stentless biologic valve
constitute a passive mechanism responding to pressure difference between the left ventricle
and the aorta. Like the native aortic valve, a stress created by this difference heads toward the
central coaptation area of the bioprosthesis during diastole. The negative pressure difference
during diastole helps prosthetic valve to be closed. The valve opens rapidly at the beginning
of ejection because of rising of pressure difference and persists to remain open as a tunnel
 
Shelhigh Suprestentless 
Figure 2. Second generation bioprostheses.
 
Sorin Pericarbon Freedom Sorin Pericarbon Freedom SOLO 3F Therapeutics 
Figure 3. Third generation bioprostheses (Pericardial Stentless Xenografts)
 
3F Enable model 6000 Perceval S 
Figure 4. Sutureless Pericardial Stentless Xenografts






I. First generation (Stentless Porcine Bioprosthesis)
Dacron reinforced inflow tract
Toronto SPV (stentless porcine valve) St Jude Medical, Inc., St Paul, MN, USA
St Jude Medical-Biocor St Jude, Belo Horizonte, MG, Brazil
CryoLife-O'Brien Model 3000 CryoLife International Inc, Atlanta, GA, USA
Toronto SPV Root St Jude Medical, Inc., St Paul, MN, USA
Edwards Prima Plus Edwards Lifesciences, Inc., Irvine, CA,USA
Medtronic Freestyle Medtronic, Inc., Minneapolis, MN, USA
pericardial reinforced inflow tract
Koehler Elan Koehler, Bellshill, Scotland
Koehler Elan Root
tri-composite design (three noncoronary leaflets)
Labcor Labcor, Inc., Belo Horizonte, MG, Brazil
II. Second generation (porcine with single suture line,
No-react treatment)
Shelhigh Suprestentless Shelhigh, Inc, Millburn, NJ, USA
III. Third generation (Stentless Pericardial Bioprosthesis)
porcine pericardium
Sorin Pericarbon Freedom Sorin Biomedica Cardio SpA, Saluggia, Italy
Sorin Pericarbon Freedom SOLO
horse (equine) pericardium
3F Therapeutics 3F Therapeutics, Inc., Lake Forest, CA, USA
IV. Fourth generation (non-gluteraldayhde fixed +
decellularized)
Matrix A
V. Sutureless generation (Sutureless + Stentless
Pericardial Bioprosthesis)
3F Enable model 6000 3F Therapeutics, Inc., Lake Forest, CA, USA
Perceval S Sorin Biomedica Cardio SpA, Saluggia, Italy
D. Autologous pericardium
Table 1. Stentless Bioprostheses.
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during systole, and the aortic root may also expanse at the late diastole to help opening of the
leaflets (in native aortic valve, expansion of the aortic root is about 12% and that starts opening
the leaflets to about 20%). At the end of systole, the backward blood flow into the sinuses of
Valsalva (behind prosthetic leaflets) and initialization of pressure difference help prosthetic
leaflets to revert to their original closed position. An in-vivo-study has showed that there is
no difference in opening velocities among native, stented and subcoronary stentless valves in
a porcine model [12]. However, the closing velocities are significantly higher in the pericardial
valves. The bending deformation increases when implanting a glutaraldehyde-treated valve
subcoronary. Porcine stentless valves display a distinct folding pattern during opening
resulting in an altered stress distribution and also tend to fold during opening causing
increased leaflet bending stress [13].
One of the key parameters for stentless xenograft performance is the EOA. In spite of the EOA
is significantly higher in stentless bioprostheses it is also dependent on the design and the
implantation technique of the prostheses. The EOA will increase especially during the first
year and the transvalvular gradient drops dramatically in the first 3 to 6 months after surgery,
but some further drop may be seen more later [14]. The reason may be remodeling of the left
ventricular outflow tract, diminished aortic root edema, and slight dilatation of the aortic root.
Transvalvular gradient is closely related to the EOA: the larger orifice area the lower is the
transvalvular gradient. The second reason to increase transvalvular gradient is usage of a rigid
stent. Avoidance of a stent enlarges inner diameter of prosthetic valve and eliminates intralu‐
minal obstruction which increases the EOA. Several studies have shown transvalvular
gradient across stentless valves is always lower than for their stented valves, especially mean
and/or peek gradients [15-1617]. The third possible reason can be excessive tissue of a bio‐
prosthesis: the lesser tissue implanted within the recipient aortic root the lesser obstruction.
The full root prostheses reduce the intraluminar obstruction because nothing is implanted
inside, and they have larger EOA than subcoronary prostheses. The main differences of
stentless biologic tissue valves are the specific gravity of the leaflets which is not equal to that
of blood like native human aortic leaflets and the specific thickness of the leaflets which is
thinner in pericardial tissue valves. Both parameters cause transvalvular gradient during
ejection which is lesser in fully pericardial stentless valves than porcine. The other reasons may
be small aortic annulus and physically active patients. The change in gradients during exercise
is interesting: when cardiac output increases it also increases the transvalvular flow and raises
transprosthetic gradient, but these gradients under exercise are lower with stentless valves
than stented bioprostheses, which provide better opening-closing behavior [18].
Left ventricular output is maintained by the development of the left ventricular hypertrophy
which results in a large pressure gradient across the stenotic valve. The left ventricle mass
increases and becomes less compliant. Left ventricular hypertrophy and increased mass can
be correlated with sudden death, congestive heart failure, and other cardiovascular events.
Left ventricular hypertrophy will regress after AVR regardless of the type of prostheses, and
an improved hemodynamic performance of prostheses should result in a faster regression,
especially in patients with severe calcific aortic stenosis and left ventricular hypertrophy,
because incomplete regression after AVR is related to poor long-term outcome [19]. This
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regression is related to EOA and transvalvular gradient constituted by the prosthetic valve. A
significant improvement will occur in all type of valves in the first year, but this improvement
is greater and faster with the stentless bioprostheses [20]. A lasting benefit beyond the first
year is possible, especially in severely enlarged ventricles [21]. These improvements include
mass regression, wall thickening, fractional shortening, and diastolic relaxation. Patients with
small aortic annuli or with compromised left ventricular function (EF < 50%) might benefit
more from stentless prostheses [22,23].
3. Structural and nonstructural durability
One of the foremost concern of any tissue valve is its long-term patency, because the limited
durability represents the main disadvantage of these devices. Tissue valve degeneration
causing stenosis or regurgitation is the primer indication for reoperation.
Durability of any kind of stentless bioprosthesis can be affected adversely by internal (struc‐
tural) or external (nonstructural) factors.
Structural valve deterioration (SVD) is a primary tissue failure after biological valve implan‐
tation. A major cause of SVD is cusp tear with consequent aortic regurgitation where urgent
or emergent reoperation is necessary due to congestive heart failure and hemolytic anemia.
The other major reason is prosthetic valve sclerosis and calcification which could permit an
elective reoperation in stable condition. An in vivo animal study has shown that native aortic
valves are significantly more distensible at the level of the sinotubular junction, commissures
and ascending aorta when compared with all-valve prosthesis [24]. There is no any study to
evaluate how the late scar with/without calcification tissue formation spread and effect this
distensibility. We can argue that annular calcification developed during follow-up acts similar
in native and stentless valves and fixes the aortic annulus. The zero-pressure fixation and
antimineralization techniques have improved durability of tissue valves. To avoid from well
known limited durability of xenogenic bioprostheses owing to structural degeneration and
calcification, the use of autologous pericardium may be an attractive alternative with several
advantages: no immune reaction, minimum tissue calcification and pannus formation,
excellent hemodynamics and dynamics of the aortic root, no complicated reoperation [11].
Nonstructural valve deterioration (NSVD) is independent on the xenograft's tissue. In spite of
leaflets of xenografts work very well, stentless bioprosthesis shows incompetence. There are
several reasons causing prosthetic stenosis or regurgitation (Table 2).
Technical inadequacy during stentless valve implantation cause hemodynamic problems like
regurgitation, turbulent flow, uncoaptation or stretching of leaflets which aggregate tissue
degeneration. Any increase in mechanical stress causing by surgical implantation techniques
has a negative impact on durability. Description of all implantation techniques with their tips
is not adequate to avoid iatrogenic valve degeneration, all details of these techniques should
be well known. The best way to avoid mechanical stress may be to use the full root replacement
technique, but most surgeon do not like to replace the aortic root without any pathology
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(dilatation, calcification) because of higher operative risk. Subcoronary implantation technique
is more acceptable approach for isolated AVR with stentless bioprostheses. Technical errors
relating to xenograft sizing and failure to achieve appropriate geometry of the xenograft within
the aortic root are 2 major reasons for early valve failure. The learning curve associated with
subcoronary implantation is the main reason for these technical errors. Suboptimal implanta‐
tion resulting in distortion of the valve or bulking of valve tissue into the outflow tract may
be involved in the evolution of higher gradients. Undersizing of xenograft results regurgitation
due to handicapping leaflet coaptation, whereas oversizing may cause higher transvalvular
gradient due to making leaflet opening difficult. The other error is to decide and apply the
wrong implantation technique, especially in small or dilated aortic root, and subcoronary
technique might be associated with higher gradient or regurgitation [25].
On the other hand, improvement of the long term patency of an aortic prosthetic valve is
dependent on avoidance of paravalvular complications which can be very serious and cause
reoperation. Paravalvular regurgitation is a dangerous long-term result of insufficient
decalcification, which causes incompetence suturing or suture rupture during follow-up.
Partial dehiscence of the stentless xenograft indeed occurs and that it has a strong predilection
for the preserved non-coronary sinus after modified subcoronary technique. Supposedly,
proteolytic enzymes from captured blood cells in the dead space between native and donor
aortas or the potential usefulness of biologic glues might prevent adequate fusion of the walls
and healing of the anastomosis [26].
A. Endocarditis
B. Technically implantation errors
C. Aortic root enlargement
I. Sinotubular junction dilatation
II. Sinus of Valsalva aneurysm (± rupture)
III. Aortic dissection
IV. Left ventricular dilatation
D. Partial dehiscence after preserved non-coronary sinus
E. Insufficiently decalcification
I. Poor decalcification (intra-operatively)
II. Suture rupture or loosening (post-operatively)
III. Calcification on the native aorta (follow-up)
F. Subvalvular fibrous band
G. Hematologic problems (hemolysis, thrombocytopenia)
Table 2. Non-structural Deterioration (regurgitation or stenosis).
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Subvalvular fibrous band is a rare complication resulting significant left ventricular outflow
tract obstruction, which can be a derivative of the pannus discovered on the sewing ring of
stented valves. The etiology is unknown, but it may result from thrombus formation or
inflammation related to host factors. A chronic inflammatory infiltrate composed of lympho‐
cytes and macrophages occurs in equine or porcine stentless valves, which suggests equal
immunogenicity among different various biologic graft materials [27].
4.1. Aortic valve surgery
4.1.1. Cardiopulmonary bypass
Aortic valve surgery can be performed through a median full sternotomy or upper minister‐
notomy with conventional or minimal skin incision. The distal ascending aorta cannulation is
usually the standard approach in most patients, but the arcus aorta or axiller artery can be also
cannulated when the ascending aorta should be replaced [28]. A single dual-stage venous
cannula is inserted through the right atrium appendage. After cardiopulmonary bypass is
initiated the aorta is clamped and cardiac arrest is be achieved with antegrade isothermic blood
cardioplegia administered into the aortic root. Myocardial protection is continued due to
retrograde cardioplegic cannula during whole procedure, and retrograde cardioplegia is
continuously infused whenever clear visulation of the aortic root is not required [29]. Rarely
the retrograde cannula cannot be introduced safely into the coronary sinus, in this situation
intermittent antegrade isothermic blood cardioplegia is performed using selective coronary
ostial cannulation after transverse aortotomy incision. If both approaches are unsuccessful,
bicaval cannulation is performed and the retrograde cannula is placed in the coronary sinus
under direct vision. A vent cannula is inserted into the left atrium through the right upper
pulmonary vein after cross clamp to prevent the left ventricle distention. Mild-moderate
hypothermia (30-32°C) is achieved and continued during extracorporeal circulation, and
rewarming of patients is started before the closure of the aortotomy.
4.1.2. Aortotomy
A small transverse aortotomy incision is made initially at least 15 to 20 mm above the origin
of the right coronary ostium or the sinotubular junction. The calcific aortic valve and whole
aortic root should be investigated under direct vision and decided which approach will be
preferred. If the aortic root will not be replaced then the transverse aortotomy incision is
extended on both sides until 3D view of the aortic root appears. That helps surgeons for
excision of the severe calcific aortic valve, selection of an appropriate stentless bioprosthesis
and insertion simple and/or continuous sutures easily and correctly. A transverse aortotomy
is also required to image 3D shape of the aortic root which is the main condition for resus‐
pention of the prosthetic commissures and to hold a stentless tissue valve in corrected position
for prevention of the iatrogenic valve degeneration. An oblique or hockey-stick incision is
preferred very seldom, but it could be useful in patients with small aortic root. If the aortic
root is replaced it is excised completely and aortic root implantation technique is performed.
Reoperation for severe calcific aortic stenosis is not rare in patients with previously coronary
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artery bypass surgery, and patent proximal anastomoses on the ascending aorta can be a
serious problem during aortotomy. I have offered a simple aortotomy incision "Reverse U
aortotomy" to save proximal anastomoses and if it is necessary to apply direct antegrade
cardioplegia through proximal anastomoses [30].
4.1.3. Excision of the calcific aortic valve
Aortic valve stenosis appears with fusion of one or both commissures, thickening and
retraction of the cusps, and restriction of effective orifice area. Calcific involvement of native
aortic valve is the last step which can be widespread very aggressively: aortic annulus, mitral
annulus, aortic root, coronary ostia. The typically pathologic findings of calcific aortic stenosis
are discrete, focal lesions on the aortic side of the leaflets. The severe form is characterized by
diffuse calcification of the aortic root and the deposits involve the sinuses of Valsalva and the
ascending aorta (porcelain aorta). The calcification presents as a cauliflower-like mass within
the leaflets and often extends deep into the annulus and surrounding tissues. All these
contiguous anatomical structures can have adverse affects on the surgical techniques.
A surgically complete decalcification of the aortic annulus is an important point. The flexible
continuity of the aortic annulus with sub- and supra-annular tissues is indispensable condition
to get better durability and hemodynamics with stentless xenografts, and to avoid from a whole
aortic root replacement technique, which hinders surgeons to perform AVR with a stentless
xenograft. Surgeons must care 1) not to leave any calcific tissue around the aortic annulus, 2)
not to allow fragments of calcium to fall into the left ventricle, 3) not to disrupt the annulus as
possible, 4) not to detach the anterior mitral leaflet from the annulus (non-coronary sinus), 5)
not to rupture subannular muscular septum (right coronary sinus), 6) not to perforate outside
the heart (left coronary sinus).
The calcific aortic valve is excised and trimmed with a scissor leaving a 2-3 mm margin at the
annulus if the annular margin of the leaflets are healthy. The frequent scenario is conversely
that and extensive calcific involvement of the whole aortic annulus is observed very often. First
of all, complete resection of the calcific aortic valve should be performed without any compli‐
cation listed above. Excision of the calcific leaflets with a scissor is usually unsuccessful and
dangerous because of breaking of calcification and falling calcium debris into the left ventricle.
The best alternative to remove the diseased tissue is excision all of them with a lancet (number
15). A folded segment of sponge or tampon is not necessary to place in the left ventricle and
it hinders to see the cavity and to remove any calcium particle. The easiest excision with the
lancet is to perforate the healthy leaflet near the annulus in partial calcified aortic valve or to
begin excision at the commissure between the non-coronary and right coronary leaflets in en-
bloc calcific aortic valve. Cutting of the calcification is begun at the nearest end and the lancet
incises the calcified valve from the healthy annular tissue. The sharp edge of the lancet should
be headed toward the calcified valve, and cutting is performed just below of calcification. The
whole calcified valve must be incised as en-block, without fragmentation. If calcification is
very heavy or invaded into the annulus it can be cut with the scissor and then the residual
calcifications will be gently crushed and removed with a rounger. After completion of the
aortic valve excision, all residual diseased and/or calcified tissue or particles should be
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removed from around the annulus. Before sizing the prosthesis, the left ventricular cavity is
flushed and irrigated with saline solution.
4.1.4. Sizing the stentless aortic bioprosthesis
The stented prostheses must fit snugly in the annulus, because a very loose or tight fit indicates
inadequate effective orifice area (patient-prosthesis mismatch) or oversizing the prosthesis.
For the truly measurement of a stented valve, the seizer should be inserted through the aortic
annulus and the same (supra-annular) or one number smaller (intra-annular) stented pros‐
thesis must be chosen.
Sizing a stentless bioprosthesis is different from stented valves. The most important phase is
the choice of an appropriate stentless bioprosthesis, and measurement of the aortic annulus
must be done with the seizer that corresponds to the specific bioprosthesis. The true seizer
should be chosen to implant the appropriate tissue valve with the optimum size. If the
prosthetic valve is too small, the inflow end obstructs the EOA which increases transvalvular
gradient and the outflow end is stretched out with decreased leaflet coaptation which causes
more regurgitation. On the other hand, oversizing to fit a larger sinotubular junction leads to
buckling of the inflow end which can produce both relative stenosis and regurgitation as well
as harmful turbulent flow. How the stentless valves sized and implanted will influence its
function and durability in future. The larger surface area of the cusps allows greater coaptation
area which reduces the risk of bioprosthesis regurgitation. This relatively larger bioprosthesis
can simplify replacement, especially the running sutures for all sinuses. But, it is imperative
to avoid over-sizing of stentless valves with the tubular structure achieved by three tabs on
the commissures, and if sizing is uncertainty the smaller prosthesis should be implanted.
In normal aortic root, the diameter of the aortic annulus is 10-15% larger than those of the
sinotubular junction and measurement of the aortic annulus is the correct way to choice an
appropriate sized stentless valve. However, most patients with calcific aortic stenosis have an
abnormal aortic root and the relationship between both diameters is usually altered. In this
situation, the diameter of the sinotubular junction is more important because the three
commissures of stentless valves are secured at approximately the level of the sinotubular
junction if not the full-root replacement technique will be used.
A cylindrical silicon seizer is more practical to measure the true valve size when both the
annulus and the sinotubular junction are measured. The rule is that the sinotubular junction
should be dominate during measuring and if there is a major difference (> 3 mm) subcoronary
implantation technique can be not used because the commissures of stentless valves are pulled
outward and cause valvular insufficiency and an alternative technique (root replacement) or
stented bioprosthesis must be used. Supra-annular sizing is the best measurement method to
choice an appropriate stentless bioprosthesis, especially during single suture line technique. I
prefer this more practical way and put the appropriate seizer into the aortic root in supra-
annular position (not into the annulus) where I put continuous proximal suture line, so I can
choice an acceptable size that is equal to the sinotubular junction size or one number larger
stentless prosthesis can be chosen if the seizer fits aortic orifice tightly in patients with aortic
root enlargement. Trans-annular measurement is adequate to get a fit stentless valve for
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subcoronary implantation in patients with normal aortic root, but preferring one size larger
prosthesis is better if full-root replacement technique will be performed or a small aortic root
is present. I never suggest to play some traction sutures at the commissures or in the nadir of
the annulus to open the aortic orifice. It can be useful during the replacement of a stented valve,
but it will be better to release the aortic root in its original shape during sizing stentless valves.
5. Implantation techniques
Stentless aortic biologic prostheses can be different in origin: autogenous, homogenous,
heterogeneous. Procuring of aortic auto- or homograft is not easy, but production of xenografts
is a sufficiently technical supply of the industry for the treatment of aortic valve diseases. All
stentless biologic valves can be implanted using different techniques: the subcoronary method,
the full root implantation technique, and the root inclusion alternative.
The subcoronary technique is the simplest method for implantation, and either a porcine root
can be adapted intra-operatively or a prefabricated tissue valve can be utilized. The main
advantages are to avoid the manipulation of coronary ostia and bleeding from suture lines.
The disadvantages could be difficulties occurring in the small aortic annulus and calcified
aortic root, and possibilities of valve insufficiency by changing the shape of the stentless valve
in a diseased aortic root [31]. Subcoronary implantation technique can be performed in two
methods: double suture lines (classic) or single suture line (simple) approach.
In classical subcoronary implantation technique, stentless valves are fixed into the host aortic
root using double suture lines. The first suture line attaches the inflow site of the stentless
bioprosthesis in the left ventricular outflow tract: annular suture line. The second suture line,
which is constructed using 1 or 3 continuous sutures, connects the outflow site of the prosthesis
with the aortic wall below the coronary ostia: supra-annular suture line. The first suture line
consists usually of interrupted sutures, but to reduce cross-clamp and cardiopulmonary times
a continuous suture can be preferred [32]. Because the conventional continuous inflow suture
line can increase the postoperative heart block risk, an alternative subcoronary technique has
been reported in which the inflow suture line is raised at the level of right-non-coronary
commissure [33].
The single suture line technique is a simple, quick, safe and reliable method to replace the
native aortic valve with a stentless valve. This approach is used for implantation of scalloped
new generation tissue valves in supra-annular position and placement of the sutures below or
through the annulus should be avoided. Running sutures avoid any prosthetic dead space
between prosthetic valve and native aortic wall, and selecting a prosthesis a size larger than
the host annulus minimizes the stress on the suture lines. These new generation pericardial
valve can have manufactured scalloped design [34] or it can be prepared by trimming away
all the extra tissue of the valve inflow side ond scalloping the outflow side [35]. If stentless
prostheses are designed with a tubular structure, the tabs on the commissures should be
attached to the aortic wall [36].
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The total root technique requires reimplantation of coronary arteries using the button techni‐
que. The main advantages are normal physiological shape of the aortic root and choice of a
larger valve in small aortic annulus, and both avoid any patient-prosthesis mismatch. The total
root technique also prevents torsions of the commissures which avoiding postoperative
prosthetic dysfunction. The main disadvantages are implantation difficulties, requirement of
interposition a vascular tubular graft between xenograft and native ascending aorta, and
xenograft aortic wall calcification making reoperation difficulty. The learning curve seems to
be more pronounced when using the total root technique, whereas single suture line technique
may be also performed by young surgeons without any problem. Surgeons decide on their
experience and the patient's anatomy pre- and intra-operatively which approach with
appropriate stentless bioprosthesis type they will use for AVR. Isolated AVR using the
subcoronary technique is the best and easiest way in calcific aortic stenosis and using single
suture line technique increases the success of implantation a stentless xenograft.
The direct suture of autologous pericardium to the aortic wall creating a new aortic valve does
not need any supporting stent, sewing ring or cuff, allowing to rebuilt 3 symmetrical aortic
cusps independent of the geometry of the native aortic valve. Harvesting a circular pericardi‐
um about 8-10 cm in diameter, treating with glutaraldehyde, sizing-cutting-shaping (a trefoil)
with a specially designed instrument, and suturing the cut pericardium mounted on a tissue
holder are the steps of this technique which does not take more time. The important goal is to
reconstruct a newly geometrically symmetric valve and to ensure adequate coaptation with
no prolapse. the suture technique is similar to the single suture line technique and running
sutures are placed onto supra-annular aortic wall.
5.1. Subcoronary implantation technique
This approach is a simple method to implant a stentless bioprosthesis. In spite of the only
handicap is the inexperience in this field, geometric thinking is the key point to perform a
successful stentless AVR using this approach. A transverse aortotomy helps to image 3D
shape  of  the  aortic  root  which  simplifies  sizing  and  implanting  a  stentless  valve.  The
proximal  suture  line  is  performed  with  the  simple  interrupted  suture  technique.  This
technique requires 18-24 sutures (4/0 Ticron or Polypropylene) which are placed in a cir‐
cular plane coursing through the aortic annulus (annular suture line) and passed through
the  inflow  end  of  the  stentless  valve  (subannular  suture  line).  All  sutures  are  passed
through the Dacron skirt  of  the bioprosthesis just  below the lowest aspect of  the cusps,
but the sutures at the native commissures must be passed through the same level of pros‐
thetic commissures to create a geometrical shape without any distortion. It is also impor‐
tant not to injury or perforate the prosthetic cusps when the needles are passed through
the skirt of the stentless valve. If the aortic annulus is weakened or destroyed pledgeted
sutures  (4/0  Ticron)  should  be  placed  in  subannular  position  to  hold  suture  securely,
which provides satisfactory buttressing effect and repairs annular ruptures. Because xeno‐
grafts are not as pliable as homografts and its inversion into the left ventricle followed by
being pulled up into the aorta may damage the device,  I  never use this maneuver.  The
prosthesis is lowered into the aortic root and sutured with its annulus to the aortic annu‐
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lus as the baseline line,  and all  sutures are tied on the skirt.  If  the prosthesis  has three
own sinuses,  at  least  the two sinuses facing the native left  and right  coronary ostia  are
scalloped out below the level of those recipient coronaries, leaving a 4-5 mm rim of pros‐
thetic tissue behind. To suture sinuses of bioprosthesis to the native aortic sinuses, three
continuous suture lines (5/0 polypropylene) are started in the nadir of each sinus below
the native coronary ostia and in the nadir of the non-coronary sinus and progress upward
to the top of three commissures (supra-annular suture line), taking care not to buckle the
stentless  tissue or  distort  the  positions  of  the  commissural  posts.  The sutures  are  taken
outside the aorta, buttressed with a pledget and tied together. The deep bites of continu‐
ous sutures on the aortic sinuses can be transverse or horizontal,  but they must be full-
thickness at the host aortic wall.  The broad bites must be taken on the aortic sinuses of
bioprosthesis to avoid any space under device. It is also important to pass the needle well
away from the margin of the stentless cusp attachment and not to injury the cusps. If the
non-coronary sinus of the stentless valve is kept intact (modified subcoronary technique),
it is not necessary to use the third suture, and the distal suture line is completed by run‐
ning along the top to join the first two sutures. A stay suture (pledgeted 2/0 Ticron) may
be placed at the top of each commissure to achieve 3D geometric shape of the device. If it
is necessary the tops are trimmed down to the level of the native aorta. The aortotomy is
closed  with  double  continuous  pledgeted  sutures  (4/0  polypropylene)  beginning  from
each edge.
5.2. Single suture line technique
It is a simple modification of the subcoronary technique and it can be performed according to
the design of stentless valve.
Classical subcoronary stentless valves could be implanted with only supra-annular running
suture line that places the stentless annulus above and along the native annulus up and around
each commissure (Sorin Freedom Solo, CryoLife O'Brien). In this approach, the device should
fit the supra-annular area because the aortic trimmed wall of stentless valves is sutured and
attached only with proximal supra-annular suture line directly to native aortic sinuses in
supra-annular position. Three polypropylene sutures are started at the nadir of each sinus and
brought progressively up to each commissural tip with the ends brought outside the aorta for
tying (as described above). Because the stentless valve will be placed supra-annular we can
choice a 1 or 2 number larger size than the true annular-size and that prevents any transvalv‐
ular gradient.
An alternative approach must be preferred in some stentless prostheses designed as having a
tubular structure. The outflow orifice is supported by 3 commissural tabs at the distal junction
of the leaflets. Inflow implantation is performed with the same running suture line, but the
tops of three commissures are equipped at an appropriate location with stay sutures (pledg‐
etless 2/0 Ticron) tied on the outside of the aorta (3f ATS, Shelhigh Superstentless). These tabs
are sewn onto the patient’s aortic wall, thereby maintaining the tubular integrity of the
prosthesis. It is imperative to achieve true-sizing. Should uncertainty arise, the smaller
prosthesis should be implanted because larger prosthesis can block a rapid and unobstructed
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opening, whereas to small prosthesis restricts of fully leaflet-opening. The same problem can
also occur with an excessive or insufficient distal traction on the tabs.
5.3. Root inclusion technique
If the original cylindrical shape of the bioprosthetic root devices wants to be preserved without
replacement of the native aortic root to avoid bleeding complication, the root inclusion
technique can be chosen. A glutaraldehyde-treated porcine aortic root is implanted inside the
patient's aortic root. But this technique is more difficult because both native coronary ostia
should be anastomosed to the prosthesis like in classic Bentall procedure. After transverse
aortotomy a proximal suture line is performed like the subcoronary technique in a circular
plane coursing below the commissures. Appropriate opening for coronary ostia are made by
excising the sinuses facing the right and left main coronary ostia and then both are sutured
continuously (5/0 polypropylene). The only difference between the root inclusion and
subcoronary techniques is that the complete sinotubular junction of the stentless valve is
preserved. This method is not used nowadays, and if this technique is preferred it should not
be used unless the root is large enough to place 23-mm or larger prosthetic root.
5.4. Root replacement technique
Complete replacement of the native aortic root is last preference for those devices. This
technique is used mostly during auto- or homograft replacement. A part of the patient's
ascending aorta with total aortic root is excised and a new glutaraldehyde-treated porcine
aorta with total aortic root is inserted using a single proximal and distal suture lines. Only
indication to prefer this approach is an extended pathology through aortic root (endocarditis,
annular abscess, porcelain aorta, dissection) if a stentless valve is used. Since the tubular 3D
geometry is not altered, its factory-tested performance is not affected by the implantation. All
aortic root is excised and both coronary ostia are separated from the root. The valve seizer
should fit in the aortic annulus and 1 or 2 number bigger stentless bioprosthesis is chosen.
Depending on the anatomical details of the native right coronary artery, the device may be
implanted anatomically or rotated to put the porcine left in the patient's right sinus. The
proximal suture line is constructed with continuous polypropylene suture or interrupted
sutures (4/0). The coronary buttons are re-implanted as the standard fashion (5/0 polypropy‐
lene). The distal end of the bioprosthesis is usually smaller than the distal native aorta, but it
can be not a problem during distal anastomosis (4/0 polypropylene).
5.5. Direct suture technique of autologous pericardium
Truly stentless AVR using autologous pericardium sutured directly onto the aortic wall
without supporting stents is a safe and feasible alternative with excellent hemodynamics of
the aortic root [11]. With the use of specially designed instruments, the sinotubular junction is
sized, the pericardium is placed on a base, and a cutting blade of the matching size is placed
on top of the pericardium, which cuts it to the required size and shape (a trefoil). The cut
pericardium is then mounted on a tissue holder to facilitate suturing it to the aortic wall. The
prepared autologous pericardium is then sutured directly onto the aortic wall close to the
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marked annulus using 4–0 polypropylene sutures. Each running suture starting from the base
of the leaflet cusp ends at each commissure where it passes through to the outside of the aorta,
at which point the knot is tied. The commissures are then securely fixed by passing another
mattress suture from inside the commissure to outside the aorta where it is tied. Leaflet
symmetry and coaptation are assessed directly at the end of the procedure before closing the
aortotomy.
5.6. Sutureless implantation technique
Aortic valve replacement with prosthetic heart valves is the treatment of choice for calcific
aortic valve stenosis. Stentless valves are the best option with larger EOA and lower trans‐
valvular gradient, but technically the implantations of these valves are more demanding
resulting in longer operation times. However, important comorbid conditions in elderly
patients referred for aortic valve replacement require alternative treatment options with
possible reductions of the extracorporeal bypass and cross-clamp times and reliable hemody‐
namic features. In order to comply with these requirements, transcatheter (transfemoral or
transapical) valves and sutureless surgical valves have been developed. The transcatheter
techniques have the advantage of being performed without circulatory bypass but leaving the
aortic calcifications in place, thereby resulting in a high degree of paravalvular insufficiency,
atrioventricular block and strokes [37]. The surgical approach has the advantage of removing
all calcifications and the valves can be optimally implanted, resulting in minimal paravalvular
leak with a low incidence of atrioventricular block and strokes; however, it requires cardio‐
pulmonary bypass. The design of sutureless bioprosthesis stems from the intention to offer an
alternative to traditional flexible stentless prostheses using conventional open-heart surgery.
Sutureless new designed bioprosthesis is a trileaflet bovine or equine pericardial valve
mounted on an expandable metal frame in nitinol (equiatomic alloy of nickel and titanium).
New designed stentless bioprostheses have several advantages: reducing cross-clamp and
cardiopulmonary bypass times, reducing related risk by placing of proximal sutures, less risk
of tearing the aortic annulus and wall, avoiding damage of the bundle of His, preventing
foreign particle embolization. The primary benefit of this aortic bioprosthesis is the potential
for surgeons to provide the same gold standard outcomes of traditional surgical AVR but
without the need for sutures, thereby facilitating less invasive or minimally invasive proce‐
dures.
The transverse aortic incision is performed 1 cm above the sinotubular junction to preserve a
segment of the ascending aorta above the prosthetic valve. Severe calcific aortic valve is
removed and aortic annulus should be decalcified for implantation (it is not necessary a
complete decalcification). To ensure the correct positioning and orientation of the prosthesis
guide-suture(s) can be used. Avoidance of proximal suture lines makes the procedure easier.
The architectural design of this new kind of bioprosthesis allows perfect function after it adapts
itself to the aortic root. They have two cylindrical ring segments: 'outflow ring' comprises
straight posts designed to support the valve and 'inflow ring' allows the prosthesis to be
anchored to the aortic root in the Valsalva sinuses and reaches a final diameter compatible
with the aortic root. The configuration of the stentless valve is perfect which allows higher
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hemodynamic performance. There are two types of sutureless aortic bioprostheses in the
market.
The Perceval S Aortic Bioprosthesis (Sorin Biomedia Cardio Srl, Sallugia, Italy) has been
introduced for minithoracotomy incision [38]. After the device is introduced and parachuted
down into aortic annulus and checking corrected position, a balloon dilatation of the inflow
ring is performed in the Perceval S valve. If the device is in malpositioning the valve can be
quickly removed using the 'χ movement' and repositioned [39]. Because there are only three
number valves (21, 23, 25), paravalvular leakage can be observed in higher incidence (4.4%
postoperatively and 4% during follow-up) which can be a result of either inadequate sizing or
due to inappropriate decalcification of the annulus [40]. For an enlarged aorta with a ratio
greater than 1.3, the predicted diameter according to body surface area represents a contrain‐
dication for this device. Early mortality (total 2.4%) and late death (total 2.5%) is acceptable
with lower transvalvular gradient (10.8 mmHg) at the first postoperative year [41].
The 3f Enable Aortic Bioprothesis (Model 6000; Medtronic Inc, Minneapolis, USA) is more
different and the implantation is more easier: after insertion the device into aortic root in
the corrected position,  only pour warmer saline  (>  30°)  onto the  device  to  fully  deploy
the Nitinol frame into its original shape [42]. If malpositioning occurs after complete de‐
ployment, rinsing with chilled saline makes the nitinol stent flexible and enhances reposi‐
tioning until the valve is correctly placed. Early clinical and hemodynamic performances
of the 3f aortic bioprosthesis are similar to those of the regular stentless aortic valves, but
both parameters  could be inconsistent  with the established stentless  valves during mid-
term follow-up: unfavorable mean gradient especially with smaller number (≤ 23 mm), in‐
complete  left  ventricular  regression,  higher  incidence  of  neurologic  complications  [43].
However, a multi-center study has shown better early and mid-term results: major para‐
valvular leakage 2.1%, neurologic events 0.7%, lower mean gradient (10.2 mmHg), lower
valve-related early mortality rate (1.4%; total 3.6%); lower late mortality rate (1.5%; total
9.6%), excellent freedom from valve-related mortality at 1-year (96.5%; hazard ratio 1.6%/
year), lower paravalvular leakage (0.8%/year) [44].
The analysis of the current outcome of the use of sutureless aortic bioprostheses must take into
consideration the preliminary nature of these devices and the relevant implantation learning
curve. There are no comparative study analyzing the outcomes of sutureless and stentless
bioprostheses, but it can be said that sutureless bioprostheses have better outcome (mortality,
neurologic deficit, renal failure, bleeding) than conventional stentless valves in high-risk
patients with aortic stenosis (such as older, female, left ventricular dysfunction, calcification
in the ascending aorta, previously cardiac operation, pulmonary or renal disease? [45].
5.7. Transcatheter (transfemoral or transapical) aortic valve implantation
The approval of transcatheter aortic valve implantation (AVI) represents a fundamental
change in the management of calcific aortic stenosis by offering an alternative to traditional
surgical AVR in carefully selected patients. Patient-selection is very strict nowadays, and AVI
is a reasonable alternative to surgical AVR in adults with severe symptomatic calcific aortic
stenosis if they have suitable aortic and vascular anatomy for transcatheter AVI and a predicted
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survival > 12 months [46]. Transcatheter AVI can be prefer in patients with severe calcific aortic
stenosis if their aortic valve is trileaflet. There are some exclusion criteria in calcific aortic
stenosis: en-block calcification (like unicusp), bicuspid aortic valve, severe massive calcifica‐
tion closely coronary ostia, small aortic annulus (< 18 mm) or large aortic orifice (> 25 mm),
thoraco-abdominal aortic or peripheral arterial pathologies. Transapical AVI is the another
alternative in patients with calcific aortic stenosis associated thoraco-abdominal aortic or
peripheral arterial pathologies.
As experience is gained and technology evolves, new areas will be met with this approaches.
The most optional area is bioprosthesis dysfunction requiring reoperation and an attractive
option is to use a AVI procedure in which the device is deployed within the previously placed
bioprosthesis: valve-in-valve. Valve-in-valve procedures require a large enough bioprosthetic
valve inserted at the index operation to prevent patient-prosthetic mismatch with the AVI
valve.
6. Special situations
Calcific aortic stenosis is a long-term disease and usually associated with other cardiovascular
pathologies. Before AVR, all these situations must be reassessmended and case-specific
operation procedure and its alternatives must be planned. If we do not think preoperatively
that any specific situation needs an intervention intra-operatively, spontaneously home-made
resolutions can be also very helpful in the theater when we decide to correct this pathology.
6.1. Proximal ascending aorta aneurysm
Severe aortic stenosis is usually combined with proximal ascending aorta aneurysm causing
by turbulent flow. The gold standard treatment is composite aortic valve and root replacement.
Several surgical teams have devised strategies to construct their homemade composite
conduits intra-operatively. It can be a mechanical valved conduit with excellent long-term
results [47]. If any contra-indication for anticoagulation therapy, a composite bioprosthetic
valved conduit will be the best alternative. Because severe calcific aortic stenosis is often an
elderly disease, improved durability of bioprostheses stimulates also their use in the setting
of ascending aorta replacement if proximal ascending aorta requires replacement in this
population. The concept of composite bioprosthetic valved conduits has also been taken up
by the industry and these conduits are already commercially available in different sizes. There
are several technical options to allow replacement of the aortic root and ascending aorta using
either stented or stentless bioprosthesis [48]. There are basically two alternatives to built a
composite graft with a stentless bioprosthesis: the subcoronary technique and the full-root
technique.
The subcoronary implantation technique requires a tubular graft and double suture lines for
device implantation is necessary. A stentless valve is placed inside a Dacron tube graft leaving
a proximal free margin (3-5 mm) and the proximal suture line of the stentless bioprosthesis is
fixed to the graft with a running mattress suture [49]. The free end of the tube graft is then
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sutured to the native annulus with pledgeted interrupted mattress sutures, and following this,
the upper circumference of the stentless valve is reimplanted within the tube graft using a
second running mattress suture. To avoid the potential drawbacks of a straight cylindrical tube
an aortic graft with pseudo-sinuses can be used [50] or David-V procedure using a stentless
bioprosthesis can be applied to build new sinuses [51]. I implant firstly tubular synthetic graft
using pledgeted interrupted mattress sutures subannularly, and then a stentless valve is
implanted using the single suture line technique as described above. The ready-to-use
composite biological valved graft is also available in practice currently [The BioValsalva
composite grafts (Sulzer Vascutek, Renfrewshire, Scotland, UK)] [52].
The full-root technique is preferred in order to reduce distortion risk leading valve regurgita‐
tion or deterioration, but the commercially available stentless porcine aortic root devices are
usually too short to replace the host ascending aorta. There are also four alternatives to suture
a stentless conduit directly to the distal ascending aorta with extended tubular devices:
extended version of stentless porcine aortic root bioprosthesis, direct anastomosis after
extensive mobilization of the host aorta, interposition of a Dacron tube graft, and total
xenopericardial valved conduit. The availability of extended root xenograft is extremely
limited, but this approach can achieve an anastomosis between xenograft and the distal
ascending aorta [53]. Primary end-to-end anastomosis might prevent the need for graft
interposition, but extensive mobilization of the aortic arch and its branches can be dangerous
and some tension might be left at the distal anastomosis with a risk of late dehiscence and false
aneurysm development [54]. The most practical technique appears to be the insertion of a
Dacron tube graft between the xenograft root and the native distal ascending aorta [55]. There
is a new bioprosthetic conduit, constructed using individual non-coronary porcine cusps,
which are fitted on a scalloped shaped tubular bovine pericardium [56]. The 15 cm long
pericardial cuff is long enough to facilitate the anastomosis between the conduit and the
remaining distal aorta. If mid- or long-term results will confirm excellent results, this option
will be an attractive alternative to the others techniques.
6.2. Small aortic annulus
Aortic valve replacement with a small stented prosthetic valve is technically straightforward
and frequently performed, but it may result in patient-prosthesis mismatch and a high residual
outflow gradient, which is significant risk factor for early mortality [57]. Patient-prosthesis
mismatch is associated with an increase in all-cause and cardiac-related mortality over long-
term follow-up, and current efforts to prevent prosthesis-patient mismatch should receive
more emphasis and a widespread acceptance to improve long-term survival after AVR [58].
When the aortic annulus diameter is less than 20 mm, a relatively high transvalvular velocity
has to be expected after valve replacement. In these cases, a stentless bioprosthesis with/
without aortic root enlargement would provide better hemodynamic results than stented
valves.
For severe small aortic root with small aortic annulus, a xenograft root replacement can be the
first alternative and this technique avoids the aortic annulus enlargement, but it can be
problematic because of reimplantation of the coronary arteries, calcified aorta and/or coronary
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ostia, or prolonged operation times. The full-root replacement technique is technically more
demanding, but it prevents residual gradient postoperatively, and if one number larger
conduit is selected the possible largest orifice area will be gained. Subcoronary techniques
with/without intact non-coronary sinus can be also used in these patients with excellent
hemodynamics in smaller valve sizes and appropriate device can be implanted safely and
easily [59].
Another alternative technique is aortic annulus enlargement to prevent patient-prosthesis
mismatch and a two-size-larger prosthesis could be inserted. The most commonly used
technique is enlargement of the aortic annulus with a biologic or synthetic patch which can be
performed in different approach [60]. A modification of the Manouguian technique has been
introduced for aortic annulus enlargement without using a patch [61]. A tubular aortic
bioprosthesis of one or two sizes larger than the size of the native annulus is prepared for
modified subcoronary implantation technique and non-coronary sinus wall be kept intact. The
prosthesis is sutured directly on the enlarged annulus after the aortic incision is extended
through the commissure, and the aorta is closed directly with the mural wall of the tubular
xenograft.
6.3. Porcelain aorta
The scope of porcelain aorta ranges from isolated plaques to the circumferential calcification
of the ascending aorta. Typically, a heavily calcified ascending aorta with calcific aortic stenosis
involves aortic annulus, aortic valve, aortic root and ascending aorta (± distal aortic segments).
This scenario is associated with higher operative mortality and morbidity than isolated severe
calcific aortic stenosis. A more recent study have been demonstrated a link between arterio‐
sclerotic changes in aortic valve and ascending aorta [62]. This study compared healthy
patients with severe aortic stenosis patients shows that the prevalence of aortic root calcifica‐
tion (26% versus 54%; p = 0.008) and of atheroma in the ascending aorta (7% versus 24%; p <
0.001) are higher in aortic valve disease patients and patients coexisting coronary artery disease
have more extensive arteriosclerotic changes in the thoracic aorta compared with those with
aortic stenosis alone and control subjects.
The operative management of severe calcific aortic stenosis with porcelain aorta can be difficult
and complex because of difficulty of clamping the ascending aorta, aortotomy, supra-annular
sutures, or aortic root replacement, and the risk of calcific embolization of major branches
(coronary, carotid, or other arteries), aortic dissection. Digital palpation with a lowered
systemic blood pressure or epiaortic sonographic evaluation can be used to confirm that there
is a softer spot in the aortic arch for cannulation intra-operatively. If there is no any healthy
site on the distal ascending aorta or aortic arch for regular arterial cannulation (34%), alterna‐
tive arterial cannulation should be performed through innominate (8%), axillary (24%) or
femoral (34%) artery [63]. There are several alternatives to perform AVR: standard replace‐
ment, endarterectomy for calcified porcelain aorta, no touch technique under circulatory arrest
(no cross-clamp, no endarterectomy, no ascending aorta replacement), total replacement of the
ascending aorta replacement (with/without circulatory arrest), apico-aortic valved conduit,
transcatheter AVI. I prefer standard AVR if it is possible, if not I perform David-V total
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ascending aortic replacement with a stentless bioprosthesis [47]. Last decade, ascending aortic
replacement is the most preferred method for the treatment of porcelain aorta, but transfemoral
[64] or transapical [65] AVI will replace the first choice of the treatment in this decade. These
alternatives demonstrate significant advantages (especially very low incidence of neurological
events, avoidance of cardiopulmonary bypass and circulatory arrest) in comparison to other
conventional techniques in the setting of severe aortic calcification.
6.4. Concomitant severe coronary artery disease
Many patients  with moderate  or  severe calcific  aortic  stenosis  have significant  coronary
disease,  suggesting  that  the  degenerative  changes  of  the  aortic  valve  leading  to  aortic
stenosis may be part of a similar arteriosclerotic process.  Coronary lesion can be also in
different coronary arteries or massif  calcification involves into coronary ostia.  Combined
surgical treatment is  the main modality,  but percutaneous coronary intervention is safer
in patients undergoing transcatheter AVI, or in patients with high risk (high comorbidi‐
ties,  reoperation,  pericardial  adhesion).  Because  hypercholesterolemia  is  related  to  in‐
creased  risk  of  aortic  valve  calcification  in  patients  with  aortic  stenosis,  preventive
treatment of hypercholesterolemia could play an important role to decrease or inhibit de‐
velopment of aortic valve calcification [66].
6.5. Concomitant hematologic disease
The best opportunity to improve the treatment of any hematologic disease or to prevent any
complication aggravating by hematologic pathologies is avoidance from prosthetic foreign
devices. Autologous tissue is the only biologic material preparing prosthetic valve, but that
can be limited because of pericardial pathologies, inadequate surgical experience or technical
problems. Mechanical valves have life-long durability with some possible hematologic
complications such as thrombo-embolism, warfarin related hemorrhage, heparin induced
thrombocytopenia, hemolysis. Prosthetic foreign material can also aggravate hematologic
diseases. To decide which prosthesis can be the acceptable choice for AVR in patients with
hematologic pathology is depend on patient's characteristics and patient-by-patient analysis
is required. Biomaterials seem better than mechanical prostheses, and stentless aortic biopros‐
theses are the best alternatives because of absence of a rigid stent, biodynamic characteristics,
larger EOA with lowest transvalvular obstruction, unnecessariness of anticoagulation, which
might decrease hematologic complications. I prefer stentless xenografts for AVR in patients
with severe hematologic pathologies [67].
Postoperative thrombocytopenia is a transient phenomenon, self–recovering after a few days
without any treatment and without any observed recurrence in late follow-up. Microhemo‐
dynamic effects of the prosthesis structure or depending on the implantation technique
and/or specific chemical preparations of biological prosthesis tissue could act as a trigger for
the post-replacement thrombocytopenia. It seems to be possible that transient unspecific
activation of platelets result in diffuse consumption and lower platelet levels. The reason for
this phenomenon is unknown and the use of consistent monitoring is necessary to prevent
severe falls in platelet count. It seems unrelated to the type of aortic bioprosthesis and I have
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not observed this phenomenon only in stentless pericardial valves, but also in different
bioprostheses [68]. However, thrombocytopenia after implantation of the stentless pericardial
xenografts can develop more common and becomes dangerous for the patient [69,70].
7. Surgical–technical complications
In spite of all implantation techniques of different stentless bioprostheses are demanding and
require an aortic valve surgical experience, some situations can make trouble AVR intra-
operatively or impair operative outcomes in the early postoperative period. Every surgeon
must be aware of these troubles and keep in mind case specific technical solutions in the theater.
7.1. Severe annular calcification
To replace the diseased aortic valve in patients with calcific aortic stenosis is a serious
intervention because of extensive calcification. Debridement of all calcium deposits back to
soft tissue improves seating of stentless prostheses in supra-annular position and provides
better performance, and may be, protects devices early calcification. I always prefer deep
debridement and decalcification of all around structures. If there is no any damage on the
annulus, I implant a stentless valve with the single suture technique (supra-annular implan‐
tation); if not, I prefer the classic subcoronary technique and use pledgeted sutures in suban‐
nular position to repair defects. Calcification after stentless valve implantation is complicated
if a stentless bioprosthesis is implanted in young patient: faster calcification in homografts has
been reported compared with xenografts [71].
7.2. Conduction disturbances
Permanent of transient conduction defects are well-known complications of aortic valve
surgery [72]. Higher degree atrioventricular blocks are often reversible and disappear before
discharge from the hospital. Approximately 5% of patients undergone isolated AVR require
permanent pacemaker implantation. Risk factors can be patient-specific: bicuspid aorta,
annular calcification, hypertension, preexisting conduction disturbances, coronary artery
disease. Surgeon-specific risk factors cause mostly mechanical injury of the atrioventricular
conduction pathways during aortic valve surgery: annular decalcification, deep suture
placement, suturing techniques, pressure on the conduction tissue. Atrioventricular block
generally results from trauma to the atrioventricular node or His bundle in the region of
membranous septum and right trigone beneath the non-coronary - right coronary cusps
commissure. The continuous inflow suture line is the most common cause for atrioventricular
block because this suture line is placed below each commissure in a horizontal plane based on
the level of the nadir of the attachments of the native aortic valve leaflets to the native aortic
valve annulus. Raising the continuous inflow suture line below non-coronary - right coronary
commissure prevents such conduction complication. Interrupted inflow sutures are also safer
than continuous technique. The best approach is the single suture line technique which does
not need any inflow suture line.




Coronary flow complications are uncommon after stentless AVR, in spite of calcific aortic valve
stenosis appears often with coronary ostia calcification with/without coronary artery disease.
Myocardial ischemia developing after AVR can develop due to several reasons. Uniform
adequate myocardial preservation during operation is the main preventive strategy. Coronary
artery bypass grafting should be added aortic valve surgery if any coronary artery stenosis is
proved angiographically before surgery. Technical or pathologic factors must also keep in
mind. Extensive calcific involvement of coronary ostia or any calcific particle embolization can
block antegrade coronary blood flow postoperatively. Endarterectomy or coronary artery
bypass grafting should be performed if not any coronary lesion is proved. Decalcification of
the aortic root may be well without any aggressive manipulation on coronary ostia, but rupture
around coronary ostia can be fatal. Implantation techniques can damage coronary blood flow
due to technical errors. Besides a learning curve for these more complex procedures, other
factors that could potentially contribute to excess myocardial ischemia or bleeding causing
coronary ostia complications. Technical problems can occur mostly during the aortic root
replacement with stentless xenografts. This type of coronary insufficiency is uncommon and
more often affects the right coronary artery [73]. Coronary buttons are prepared for suturing
to xenografts, but they can be damaged because of extensive cutting, dissection, or aggressive
decalcification of buttons. Severe tension on the button anastomoses can cause bleeding,
rupture, kinking or obstruction. Preventive maneuvers are recognition of coronary orientation,
routine xenograft rotation, adequate coronary button mobilization, oversizing xenograft. The
subcoronary implantation is more secure procedure than the root replacement technique and
technical complication causing coronary problems can occur very seldom if running sutures
bite very close to the coronary ostia.
7.4. Dehiscence
Partial or severe dehiscence of aortic prosthetic valves is a serious, but very rare complication.
Complete dehiscence occurs with sudden death and it is not seen during practice life. Demand
on the severity of dehiscence, the clinic scenario can be variable. Limited dehiscence can be
silent and stable, more serious dehiscence shows some signs and unstable. If the aortic root
replacement technique is preferred dehiscence can be very small at the proximal or distal
suture line which presents bleeding, hematoma or massif hemorrhage. Dehiscence observed
after the subcoronary implantation technique is associated with aortic regurgitation, but using
obliterating sutures prevent usually this complication. In the aortic root inclusion technique,
the dead space between native and donor aortas might be prevented adequate fusion of the
walls and healing of the anastomoses, which is observed mostly in non-coronary sinus [74].
Any symptomatic dehiscence investigated by echocardiography intra- or early postoperatively
should be repaired and a reoperation should be performed immediately. In the absence of
valve dysfunction, progressive dehiscence, or the development of thrombus a reoperation can
be not necessary and conservative management will be safe during early- and long-term
follow-up [75].
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7.5. Progressive sinotubular junction dilatation
This late postoperative complication is observed in some stentless xenografts when they are
implanted with the subcoronary technique. Currently, little is known of the diastolic properties
of stentless valves that affect stress and strain on leaflets and, hence, their durability. Despite
similar systolic performances, stentless prostheses behave differently during diastole. The
commissures of the stentless bioprostheses have to follow the dimensional changes of the
native aortic root not only in a cyclic mode but also the increase of the aortic diameter [76].
This change pulls apart the commissures leading to reduction of coaptation area of the cusps
and late aortic insufficiency develops. Aortic regurgitation is often mild or moderate depend‐
ing on bioprosthesis type, especially in old generation, but re-operation rate is low. In a
pressurized aortic root model, a series of in-vitro tests is conducted to determine how stentless
valves behave in diastole, and how they adapt to different annulus-to-sinotubular junction
(STJ) ratios [77]. Pericardial prostheses built to mimic a cylinder (ATS 3F and Sorin Solo)
showed the greatest tolerance to STJ dilatation and a larger coaptation surface, but also a
tendency to roll in on themselves in an italic S-shape if oversized. Valves built to mimic native
aortic leaflets (porcine Prima Plus and Medtronic Freestyle) showed a reduced tolerance to STJ
dilatation, resulting in regurgitation and a smaller coaptation surface, but also a reduced
tendency to roll if oversized.
A significant difference of tolerance against aortic regurgitation with respect to dilatation of
the sinotubular junction was found in an in vitro study: fresh porcine aortic root (higher) >
fresh porcine pulmonary root > stentless porcine bioprosthesis (lower) [78]. This loss of
adaptability may be related to the glutaraldehyde fixation leading stiffness and shrinkage of
the bioprosthetic leaflets which leaves inadequate coaptation reserve. An increase of sinotub‐
ular junction diameter of more than 32% for the Toronto SPV and 43% for Medtronic Freestyle
stentless valves results in a distinct loss of leaflet coaptation and causes aortic regurgitation.
New generation of pericardial stentless valves developed for subcoronary implantation have
larger coaptation area than those old generation or porcine stentless valves, which may provide
better adaptability to adverse changes in root dimensions [79]. With massif progressive
stepwise dilatation at sinotubular junction level, the free edges of the leaflets are stretched
wider and a triangle-shaped central coaptation defect will occur. For the 3F Aortic valve
regurgitation started at approximately 156% of the labeled valve size and 145% for the Sorin
Solo valve. The increased tolerance of pericardial bioprostheses may improve long-term valve
performance, but durability of these valves may be affected by the redundant leaflet tissue
leading increase of leaflet stress and degeneration.
To overcome this disadvantage of stentless valves, a slight oversizing of the devices may result
better valve competence and hemodynamic efficiency compared to size-for-size implantation.
Sizing with a supra-annular seizer is helpful to find the largest stentless valve number which
is minimum equal to the sinotubular junction diameter in patients with healthy aortic root.
The single suture line technique is fixed prosthetic sinuses onto the native aortic wall to prevent
any leakage or stretching.
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7.6. Reoperation of a stentless aortic bioprosthesis
Stentless aortic valve reoperations may become more common as these bioprostheses reach
the limits of their durability, which are a challenging procedure with an increased risk of death
[80].The current generation of stentless valves have been implanted since the early 1990s and
are therefore starting to reach the limits of their durability. Reoperation for stentless valves is
a complex procedure, especially root inclusion or full-root replacement was preferred. The risk
of trauma to the coronary ostia, aortic wall, aortic annulus, anterior mitral valve, and mem‐
branous septum can all occur when severe adhesions or calcification are present around the
stentless valve. Reoperation after a stentless valve is more complex than after a stented tissue
or mechanical valve if root replacement techniques is used in the first operation. However,
reoperation of subcoronary implanted stentless bioprosthesis is easier than any stented
prosthesis because cutting only the suture line is enough to remove the degenerated biopros‐
thesis. Valve-in-valve replacement with transfemoral [81] or transapical [82] AVI is a more




Risk of death is highest immediately after AVR in patients with severe aortic stenosis,
decreased to its nadir approximately 1 year postoperatively (early hazard period), and then
gradually increased (late hazard period) [83]. From approximately 2 years after operation,
survival is similar to that of matched population estimates. Early outcome of patients with
aortic stenosis after AVR is primarily influenced by severity of the stenosis, left ventricular
hypertrophy and dysfunction at operation. Severity of aortic stenosis, severe left ventricular
hypertrophy, left ventricular dysfunction, older age and patient-prosthesis mismatch worsen
also long-term survival. Furthermore, stentless AVR requires longer cross-clamp and cardio‐
pulmonary bypass times.
Several meta-analysis studies confirm that stentless AVR does not worsen the early and late
outcome when compared to stented bioprostheses. Also, longer operation times do not have
any adverse effect on the intra-operatively mortal complications and postoperative outcomes.
Contrarily, early recovery of hemodynamic malfunctions caused by calcific stenotic native
aortic valve brings better early and late outcomes.
Hospital mortality rate of stentless bioprostheses is lower than those of stented xenografts
[84,85]. Early hospital or 30-day mortality is similar between stentless and stented biopros‐
thesis replacement in a meta-analysis (3.2% versus 2.4%; p = 0.39), and further analysis of 30-
days mortality is subgroups included predominantly patients with aortic stenosis shows still
no significant difference between two types of aortic bioprosthesis (3.7% versus 2.6%; p = 0.44)
[86]. Only one retrospective multicenter study has shown if stentless valves are used only in
selected patients (older age, female, full-root replacement) the 30-day mortality is increased
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when compared with stented valves (7.5% versus 3.3%; p = 0.026), but if stentless valves are
used widely there is no significant difference in operative mortality between stentless and
stented groups [87].Using autologous pericardium does not worse the early hospital outcome
and early mortality is not seen [11].
Several studies showed an improved mid-term (< 10 years) survival after stentless AVR
compared to stented valves [88,89]. A meta-analysis shows that mortality at the first year is
lower after stentless aortic bioprosthesis replacement than stented bioprosthesis, but not
significant: 7.5% versus 8.9%; p = 0.73 [15]. Another meta analysis also confirm no significant
difference for valve-related mortality between stentless and stented xenograft replacement in
the first postoperative year [86]. Lehmann and associates [89] showed in a randomized trial
that 8-year survival was 78.1% ± 3.8% stentless versus 66.7% ± 4.9% stented (p = 0.03). They
concluded that there was no difference in survival when compared stentless patients with an
age-matched German control population.
The long-term results (≥ 10 years) with stentless valves are excellent [90]. The overall 10- and
15-year survival rates of Freestyle bioprosthesis are 60.7% and 35%, respectively [91]. The 10-
year actuarial survival (44.1% ± 4.3% in subcoronary, 47.3% ± 8.15 in full-root, and 45.4% ±
13.7% in root inclusion groups; p = 0.89) and freedom from valve-related death (94.5% ± 2.9%
in subcoronary, 92.9% ± 5.8% in full-root, and 87.8% ± 12.5% in root inclusion groups; p = 0.17)
are similar between implants techniques with the Freestyle stentless bioprosthesis [92]. Longer
follow-up (> 15 years) of stentless valves is also necessary to compare the excellent results of
stented valves to establish that stentless xenografts are significantly superior than stented
devices.
8.2. Durability
The rate of structural valve deterioration increases over time, especially after the initial 7 to 8
years after implantation. Structural degeneration increases long-term events and the rate of
failure is < 1% at 10 years in patients older than 65 years [93]. Pericardial valves might be better
than porcine valves, but all newer-generation bioprostheses are more durable. In spite of the
rate of failure of any bioprosthesis decreases with the age of the patient at the time of implan‐
tation (< 10% at 10 years in patients older > 70 years), the number of implanted stentless
xenografts has increased due to improved hemodynamic performance and long-term dura‐
bility during last decade. Theoretically, xenogenic stentless aortic valves have better durability
than stented valves. But in real life, the freedom rate from structural valve deterioration is
similar in stentless and stented bioprostheses (> 90% at 10 years). CryoLife O'Brien and St Jude
Toronto SPV valves have worst durability compared the other stentless valves (Medtronic
Freestyle, Edwards Prima, St Jude Biocor, Sorin Pericarbon and Solo, ATS 3f).
When we focus on the implantation techniques, there are very rare papers in the literature.
The overall freedom from reoperation with Freestyle stentless bioprosthesis is 91.0% and 75.0%
at 10 and 15 years, whereas freedom from reoperation for structural valve deterioration was
95.9% and 82.3%, respectively. At 10 and 15 years, freedom from reoperation for structural
valve deterioration is 94.0% and 62.6% for patients < 60 years of age and 96.3% and 88.4% for
patients ≥ 60 years of age (p = 0.002) [90]. The actuarial freedom from reoperation (91.7% ± 3.5%
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in subcoronary, 92.3% ± 6.0% in full-root, and 92.0% ± 10.7% in root inclusion groups; p = 0.82)
and from structural valve deterioration (97.0% ± 2.2% in subcoronary, 96.0% ± 4.5% in full-root,
and 90.9% ± 11.2% in root inclusion groups; p = 0.54) are similar between implants techniques
with the Freestyle stentless valves [91].
The truly stentless autologous pericardial aortic valve may be better choice in patients who
cannot or do not want to take anticoagulation, especially young population, because excellent
long-term durability and easier reoperation, which is technically undemanding compared to
other stentless bioprostheses. The use of autologous pericardium avoids any immune reaction
between the host and the implanted valve, and minimizes tissue calcification and pannus
formation, which are important causes of structural valve deterioration. The absence of a stent
and sewing ring is also helpful for long-term durability with a freedom from structural valve
deterioration of 100% at 7.5 years [11]. Long-term durability seems better than the other
bioprostheses because it has been reported that there is no calcification, no structural dys‐
function on the autologous pericardium used for aortic leaflet extension at 13 years [94].
Reoperation must be easier because there is no calcification on the aorta and pericardial aortic
valve.
8.3. Echocardiographic outcomes
The advantage of stentless xenografts is providing a greater EOA index for a given valve size,
which results lower transvalvular gradients compared with stented valves. These improve‐
ments have been reported in a meta analysis: lower mean aortic valve gradient (-3.57 mmHg;
p < 0.01), lower peak gradient (-5.8 mmHg; p< 0.01), but higher EOA index in stentless group
compared with the stented [15]. It has been shown in an experimental porcine model that the
annular cross-sectional area of stentless valves is significantly larger than stented valves [23].
The EOA will increase after first postoperative year in stentless valves and significant differ‐
ences in mean and/or peak pressure differences between stentless and stented valves will
continue during long-term follow-up [95,96].
The Freedom SOLO stentless bioprosthesis with all size-number has a lower mean (10.6 ± 3.6
mmHg) and peak (15.9 ± 9.1 mmHg) transvalvular gradient at discharged, and below 10 mmHg
in all sizes (21-27 mm) at the first postoperative year [97]. The similar results have been shown
by other groups: lower mean gradient (6.7 +/- 4.1 mmHg) and a significant regression of left
ventricular hypertrophy (23%) at 12 months [98].
3f aortic bioprosthesis has a satisfactory hemodynamic performance with substitutes larger
than 23 mm (< 10 mmHg), but smaller valves have a significant higher mean transvalvular
gradient at the 4-postoperative year (18 mmHg for 21 mm and 14 mmHg for 23 mm devices)
[36]. The left ventricular mass index decreases during follow-up (showed 18% regression), but
cannot reach the normal range, especially with small devices. In another study with a mean
valve size 26.0 ± 1.9 mm has shown that the mean transvalvular gradient of 3f bioprostheses
has increased at 5 years (15.2 ± 5.3 mmHg) [99].
The Edwards Prima Plus stentless valve bioprosthesis is a porcine aortic root cylinder and is
associated with high early peak and mean transprosthetic gradients (37 ± 16 and 18 ±8 mmHg,
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respectively), which regress with significant improvement at 1 year (25 ±7 and 12 ±4 mmHg,
respectively) and concomitant regression of left ventricular hypertrophy [100]. The Edwards
Prima Plus stentless xenograft implanted with intact non-coronary sinus technique prevents
the geometry of the device and has excellent long-term result (mean gradient < 10 mmHg) in
all sizes (21-29 mm) [101].
There  are  some  studies  showing  different  results  regarding  transaortic  gradient,  which
might  be a  result  of  different  stentless  xenografts  or  implantation methods.  There is  no
any significantly difference among implantation techniques when the same stentless xeno‐
graft is used with different implantation techniques, but full root (4.8 mmHg) or root in‐
clusion  technique  (5.1  mmHg)  has  lower  mean  transvalvular  gradient  than  the
subcoronary technique (7.2 mmHg) [102]. Transvalvular gradient and EOA are significant‐
ly worse in subcoronary groups in the first postoperative period, but this difference will
be insignificant due to decreasing EOA and root inclusion approach will have the worst
hemodynamics at 10th postoperative year [90].
Stentless valves are the best choice in patients with small aortic annuli than large annuli,
because the lower transaortic pressure difference of stentless valves has no any significant
advantage over stented bioprostheses if a valve larger than 23 mm will be used [103]. The
difference will be significantly when a stentless valve sized 23 mm is used (Freestyle in‐
clusion  11  mmHg versus  Perimount  25  mmHg)  [21].  The  Freedom SOLO stentless  bio‐
prosthesis  seems to  have  better  hemodynamics  even in  patients  received a  small  aortic
bioprosthesis with a lower mean transvalvular gradient (9 ± 2.9 mmHg for 21 mm, and
7.6 ± 5 mmHg for 23 mm) [97].
Physically active patients might benefit from stentless valves. Several studies showed that the
gradient difference between different aortic stentless and stented bioprostheses of similar size
with different implantation techniques increased significantly at each exercise level in favour
of stentless valves [104-105106].
9. Conclusion
Aortic valve replacement means that native valve disease is replaced with prosthetic valve
inadequacy affected by prosthetic valve hemodynamics, durability, and thrombogenicity.
Stentless bioprostheses have better hemodynamic properties because of larger effective orifice
area, better coronary flow, lower transvalvular gradient and better left ventricular mass
regression than stented bioprostheses. They have also better biomechanical properties and the
preserved distensibility may diminish stress considerably. Valve-related morbidity and
structural valve degeneration are not worse than stented valves, but their implantation is
demanding and required experience in this field. Although experienced centers give excellent
results with stentless xenografts, most surgeons also prefer a stented xenograft to keep the
procedure quick, safe, and simple. But, there is a trend to favor stentless valves nowadays
because these valves provide larger effective orifice area, lower transvalvular gradients and
excellent hemodynamics which stimulate rapid and effective reduction in left ventricular
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hypertrophy. It seems that the usage of stentless valves has more advantages in patients with
impaired left ventricular function, small aortic, or aortic root abscess or more active patients.
In future, using of stentless valves will increase with simpler implantation techniques,
increased surgical experience, new design of prostheses, may be, using sutureless valves.
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